Q
Quantum Cyber N.V.
Period
FY 2025
Revenue
$537.1K
Net Income
$-16.20M
Total Assets
$5.33M
Equity
$641.6K
Shares Out
14.66M
Op. Cash Flow
$-10.98M
Business
Quantum Cyber N.V. develops in-vitro diagnostic tests for early cancer detection, historically focusing on colorectal cancer screening but now concentrating on pancreatic cancer detection. The company offers ColoAlert, a CE-IVD certified stool-based test for colorectal cancer, which it sold in March 2026, and is developing blood-based and stool-based pancreatic cancer screening tests using licensed mRNA biomarkers and proprietary algorithms. The company operates primarily in European markets and is transitioning its strategy toward post-quantum cybersecurity while maintaining diagnostic commercialization efforts.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Total revenue | 537,080 | 893,991 | |
| Cost of revenue | 147,288 | 319,108 | |
| Gross profit | 389,792 | 574,883 | |
| Sales and marketing | 4 | 7 | |
| Research and development | 5 | 6 | |
| Research and development related party | 54,775 | 121,249 | |
| General and administrative (Note 2) | 5 | 7 | |
| Impairment of intangible asset | 3 | — | |
| Restructuring expense | — | 277,160 | |
| Total operating expenses | 17 | 19 | |
| Loss from operations | −16 | −19 | |
| Other income | 42,180 | 90,561 | |
| Government grant | 533,503 | 46,087 | |
| Gain on sale of subsidiary | — | 28,328 | |
| Change in fair value of convertible debt | 21,000 | −2 | |
| Gain (loss) on sales and disposal of assets | −163,248 | 46,818 | |
| Interest expense | −373,458 | −945,545 | |
| Other expense | −131,597 | −39,817 | |
| Total other expense | −71,620 | −3 | |
| Loss before income tax | −16 | −22 | |
| Income tax provision | — | — | |
| Net loss | −16 | −22 | |
| Foreign currency translation adjustment | −69,023 | −96,319 | |
| Total comprehensive loss | −16 | −22 | |
| Basic loss per ordinary share (in Dollars per share) | −2.7 | −21.91 | |
| Diluted loss per ordinary share (in Dollars per share) | −2.7 | −21.91 | |
| Basic Weighted average number of ordinary shares outstanding (in Shares) | 6 | 985,717 | |
| Diluted Weighted average number of ordinary shares outstanding (in Shares) | 6 | 985,717 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash | 889,091 | 6 | — | |
| Accounts receivable | 17,348 | 33,577 | — | |
| Inventories | 216,888 | 372,870 | — | |
| Prepaid expenses and other current assets | 657,310 | 1 | — | |
| Total current assets | 2 | 8 | — | |
| Property and equipment, net | 1 | 1 | — | |
| Intangible assets | 1 | 3 | — | |
| Right-of-use assets | 1 | 1 | — | |
| Total assets | 5 | 14 | — | |
| Accounts payable and accrued liabilities (Note 2) | 936,440 | 3 | — | |
| Loan payable | 183,706 | 176,814 | — | |
| Convertible debt | 82,305 | 1 | — | |
| Notes payable - Silent partnership | 956,902 | 1 | — | |
| Intellectual property acquisition liability | 487,785 | — | — | |
| Intellectual property acquisition liability current portion - related party | 676,096 | 690,575 | — | |
| Operating lease liabilities - current portion | 356,126 | 264,982 | — | |
| Total current liabilities | 4 | 6 | — | |
| Operating lease liabilities | 992,480 | 945,203 | — | |
| Intellectual property acquisition liability - related party | — | 376,096 | — | |
| Total liabilities | 5 | 8 | — | |
| Ordinary shares, a par value of 0.01, 11.250.000 shares authorized, 9,780,142 and 2,319,353 shares issued and outstanding, respectively | 107,820 | 23,054 | — | |
| Additional paid-in capital | 106 | 95 | — | |
| Accumulated deficit | −105 | −89 | — | |
| Accumulated other comprehensive loss | −617,654 | −548,631 | — | |
| Total shareholders equity | 641,600 | 6 | 3 | |
| Total liabilities and shareholders equity | 5 | 14 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Share based compensation | 1 | 986,920 | |
| Stock option expense (Note 2) | 1 | −63,117 | |
| Depreciation and amortization | 615,720 | 696,629 | |
| Impairment loss | 3 | 47,449 | |
| Bad debt recovery | — | −11,919 | |
| Inventory write down | 312,151 | 186,338 | |
| Accretion expense | 202,801 | 157,703 | |
| Change in fair value of convertible debt | −21,000 | 2 | |
| Non-cash lease expense | 277,036 | 367,314 | |
| Accounts and other receivable, net | 114,630 | 20,554 | |
| Accounts receivable - related party | −43,792 | −17,238 | |
| Inventories | −99,561 | 29,811 | |
| Prepaid expenses and other assets | 791,288 | 109,246 | |
| Accounts payable and accrued liabilities (Note 2) | −2 | 210,017 | |
| Accounts payable and accrued expense - related party | 3,557 | −22,303 | |
| Deferred revenue | — | −135,724 | |
| Operating lease liabilities | −326,730 | −269,016 | |
| Net cash used in operating activities | −11 | −17 | |
| Proceeds from sale of subsidiary - related party | — | 32,785 | |
| Payment for intangible asset | −700,000 | — | |
| Payment for intangible asset-related party | −350,000 | −150,000 | |
| Purchase of property and equipment | −1,216 | −104,949 | |
| Proceeds from sales of property and equipment | 17,815 | 23,347 | |
| Net cash used in investing activities | −1 | −198,817 | |
| Sale of ordinary shares, pre-funded warrants, and warrants | 8 | 14 | |
| Proceeds from convertible debt | — | 4 | |
| Repayments of convertible debt | −1 | −1 | |
| Payments on silent partnerships | −243,405 | — | |
| Payments on loan payable | −241,816 | −103,799 | |
| Net cash provided by financing activities | 7 | 17 | |
| Effect of changes in exchange rates | −96,631 | −98,269 | |
| Net change in cash | −5 | −835,255 | |
| Interest expense | 178,563 | 150,021 | |
| Income tax | — | — | |
| Right-of-use asset additions | 312,021 | 48,272 | |
| Acquisition of intangible asset for structured payments | 1 | — | |
| Issuance of ordinary shares for conversion of debt | — | 10 | |
| Payable offset by sale of asset | 13,680 | — | |
| Loan payable for prepaid insurance | 240,826 | 277,289 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Quantum Cyber N.V.'s CIK number?
Quantum Cyber N.V.'s SEC CIK number is 0001874252 (1874252). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Quantum Cyber N.V.'s SEC filings?
All of Quantum Cyber N.V.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.